Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT04346381
Phase
PHASE2
Status
Completed

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Intravenous (IV) camrelizumab on Day 1 of each cycle
  • Famitinib — DRUG
    famitinib po qd

Study Details

This is an open-label, multi-center study to evaluate the anti-tumor activity and safety of camrelizumab combined famitinib in subjects with selected advanced solid tumor.

Key Dates

Start date
Jun 5, 2020
Status verified
Sep 2023
Primary completion
Jun 22, 2022
Completion
Jun 22, 2022

Study Design

Enrollment
233 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: camrelizumab combined with famitinib
    Participants will receive camrelizumab on Day 1of each cycle and famitinib qd up to 2 years.

Primary Outcome Measure

Response Rate [ Time Frame: Up to 18 months ]

Related Studies